EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors

Zhe Peng, Bernhard Gillissen iD, Antje Richter, Tobias Sinnberg iD, Max S Schlaak, Jürgen Eberle iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25063453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Zhe Peng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Skin Cancer Centre Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. Hauptthemen laut MEDLINE: Melanoma, Antineoplastic Agents, Pyrimidines, Thiophenes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent advances in melanoma therapy have significantly improved the prognosis of metastasized melanoma. However, large therapeutic gaps remain that need to be closed by new strategies. Antiapoptotic Bcl-2 proteins critically contribute to apoptosis deficiency and therapy resistance. They can be targeted by BH3 mimetics, small molecule antagonists that mimic the Bcl-2 homology domain 3 (BH3) of proapoptotic BH3-only proteins. By applying in vitro experiments, we aimed to obtain an overview of the possible suitability of BH3 mimetics for future melanoma therapy. Thus, we investigated the effects of ABT-737 and ABT-263, which target Bcl-2, Bcl-xL and Bcl-w as well as the Bcl-2-selective ABT-199 and the Mcl-1-selective S63845, in a panel of four BRAF-mutated and BRAF-WT melanoma cell lines. None of the inhibitors showed significant effectiveness when used alone; however, combination of S63845 with each one of the three ABTs almost completely abolished melanoma cell survival and induced apoptosis in up to 50–90% of the cells. Special emphasis was placed here on the understanding of the downstream pathways involved, which may allow improved applications of these strategies. Thus, cell death induction was correlated with caspase activation, loss of mitochondrial membrane potential, phosphorylation of histone H2AX, and ROS production. Caspase dependency was demonstrated by a caspase inhibitor, which blocked all effects. Upregulation of Mcl-1, induced by S63845 itself, as reported previously, was blocked by the combinations. Indeed, Mcl-1, as well as XIAP (X-linked inhibitor of apoptosis), were strongly downregulated by combination treatments. These findings demonstrate that melanoma cells can be efficiently targeted by BH3 mimetics, but the right combinations have to be selected. The observed pronounced activation of apoptosis pathways demonstrates the decisive role of apoptosis in the loss of cell viability by BH3 mimetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntineoplastic AgentsPyrimidinesThiophenesHumansMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2bcl-X ProteinApoptosisCaspasesCell Line, Tumor

Stichwörter der Autor:innen

BH3 mimeticsapoptosis inductionapoptotic pathwaysmelanomaskin cancertherapeutic strategies

Substanzen

S63845Myeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2bcl-X ProteinCaspasesAntineoplastic AgentsPyrimidinesThiophenes

Autor:innen und Institutionen

  • Skin Cancer Centre Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
  • Clinical Medicine, University of South China, Hengyang 421001, China.
  • Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13125 Berlin, Germany.
  • Division of Dermatooncology, Department of Dermatology, University of Tübingen, 72076 Tübingen, Germany.

ORCID-Profile: Bernhard Gillissen, Tobias Sinnberg, Jürgen Eberle

Zitieren

APA

Peng, Z., Gillissen, B., Richter, A., Sinnberg, T., Schlaak, M. S., & Eberle, J. (2024). Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063453

Vancouver

Peng Z, Gillissen B, Richter A, Sinnberg T, Schlaak MS, Eberle J. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25063453

BibTeX
@article{Peng2024,
  author = {Peng, Zhe and Gillissen, Bernhard and Richter, Antje and Sinnberg, Tobias and Schlaak, Max S and Eberle, Jürgen},
  title = {Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25063453}
}
Kostenlos starten →